By Damian Jones, ICC
- PGRs had no effect on yield, dry matter produced, plant height or depth of podding in 2015.
- Pod height was reduced when a PGR and fungicide mix was applied at budding.
- Currently no PGRs are registered for use on canola in Australia.
With little result last season, we repeated a trial in 2015 looking at alternative timings for the application of the PGRs and two products (Reward or mepiquat and Prosaro) that were not tested in 2014.
Note: There are currently no PGRs registered for use on canola in Australia, although there are products available here intended for alternative purposes that are registered for use as a PGR overseas. Therefore this information is only presented as experimentation and not for broadacre use.
The PGR treatments used in this trial were as follows:
- Cyccocel (Chloremequat) + Tebuconazole (PGR + triazole fungicide)
- Prosaro (triazole fungicide)
- Reward (mepiquat)
- Marvel (trinexapac-ethyl)
The PGRs were applied at either green buds visible or at the beginning of flowering to Garnet canola sown April 24.
The plots were windrowed on November 2 and harvested on November 17.
Dry matter (DM) was assessed just prior to windrowing.
Plant height (total length of the plant from the base of the stem to the tip of the plant) was recorded.
Podding height (length of the podded area on the plant, from first to last pod) was also recorded.
Table 1: Yield, dry matter, plant height and pod height of canola following PGR application.
|Plant Ht (cm)||Pod Ht (cm)|
|Cycocel + Teb||Budding||3.42||9.32||106.6||67.3|
|Cycocel + Teb||Yellow||4.01||12.47||115.4||73.7|
All the data presented shows that the PGRs applied had no effect on either yield, total dry matter produced, plant height or depth of podding.
The only treatment that may be worth pursuing is the Chlormequat/Tebuconazole mix at an earlier application.
The stubble project – maintaining profitable farming systems in Victoria and Tasmania with retained stubble (project number BWD00024) is funded by the GRDC.
A printer-friendly version of this trial report can be accessed here.